LK 120 The rapid adoption and evolution of liquid biopsy technology in oncology diagnostics |
LK 120 The rapid adoption and evolution of liquid biopsy technology in oncology diagnostics Guardant Health The pace of adoption of liquid biopsy by the U.S. oncology community has few peers in the history of cancer care. This rapid adoption has sparked a wave of investment and interest in similar technology... Read more |
Description
The pace of adoption of liquid biopsy by the U.S. oncology community has few peers in the history of cancer care. This rapid adoption has sparked a wave of investment and interest in similar technology from large biotechnology companies, venture capitalists, and numerous startups.
Liquid biopsies were originally introduced as a tool to help match advanced cancer patients with an appropriate targeted therapy, while sparing them the discomfort and risk of an invasive tissue biopsy. But the greater promise lies in the ability of a blood test to surveil for cancer and assuage the concerns of high-risk populations, whether they have inherited cancer risks, environmental exposures, or are cancer survivors.
As genomic sequencing costs drop, technology improves, and test sensitivity increases, new applications will emerge.
In this session Guardant Health CEO Helmy Eltoukhy will discuss:
- The rapidly evolving liquid biopsy commercial landscape
- The potential for new applications beyond what has already been commercialized today
- The process of building and iterating a digital-molecular product in a regulated environment
